|Toxiciy Grade:||4||City/State/Province:||Dallas, Tx|
|Treatments:||Chemotherapy||Hospital:||Sammons Cancer Center|
Patients: This Phase II study involved 42 men with hormone-refractory metastatic prostate cancer. Metastatic sites include bone and viscera. The median age was 73 years. Most patients had surgery, radiation therapy, or hormone therapy prior to the study. Only one patient had prior chemotherapy.
Treatment: Treatment consisted of one chemotherapeutic agent: irofulven.
Toxicity: Grade 4 toxicities consisted of thrombocytopenia, anemia, and neutropenia. Grade 3 toxicities included asthenia, vomiting, nausea, and infection.
Results: Median overall survival was not reported, but median progression free survival (the interval before half of the patients had their tumors return or grow) was 3.2 months.
Support: MGI Pharma financially supported this study, and several of the authors have relationships with MGI Pharma. MGI Pharma manufactures and/or markets irofulven.
Correspondence: Neil Senzer, MD